About the Company
Fluidigm focuses on the most pressing needs in translational and clinical research, including cancer, immunology, and immunotherapy. Using proprietary CyTOF® and microfluidics technologies, it develops, manufactures, and markets multi-omic solutions to drive meaningful insights in health and disease, identify biomarkers to inform decisions, and accelerate the development of more effective therapies. Its customers are leading academic, government, pharmaceutical, biotechnology, plant and animal research, and clinical laboratories worldwide. Together with them, the Company strives to increase the quality of life for all.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $FLDM News
Standard BioTools (LAB) Price Target Decreased by 10.42% to 3.65
The average one-year price target for Standard BioTools (NasdaqGS:LAB) has been revised to 3.65 / share. This is an decrease ...
Is Now The Time To Look At Buying Standard BioTools Inc. (NASDAQ:LAB)?
Standard BioTools Inc. (NASDAQ:LAB), might not be a large cap stock, but it led the NASDAQGS gainers with a relatively large price hike in the past couple of weeks. Shareholders may appreciate the ...
TD Cowen Initiates Coverage of Standard BioTools (LAB) with Buy Recommendation
Fintel reports that on April 16, 2024, TD Cowen initiated coverage of Standard BioTools (NasdaqGS:LAB) with a Buy ...
How Stable And Growing Is Standard BioTools Inc (NASDAQ: LAB)?
A comparison of Standard BioTools Inc (LAB) with its peers suggests the former has fared considerably weaker in the market. LAB showed an intraday change of 3.40% in last session, and over the past ...
Standard BioTools Introduces New High-Throughput Multiplexed Whole Slide Imaging Modalities Set to Redefine the boundaries of Tissue Imaging
SOUTH SAN FRANCISCO, Calif., April 08, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health ...
Standard BioTools Inc. (NASDAQ:LAB): Are Analysts Optimistic?
We feel now is a pretty good time to analyse Standard BioTools Inc.'s ( NASDAQ:LAB ) business as it appears the ...
Standard BioTools Inc LAB
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Standard BioTools Introduces New High-Throughput Multiplexed Whole Slide Imaging Modalities Set to Redefine the boundaries of Tissue Imaging
New advancements, including automation, aim to fast-forward spatial biologySOUTH SAN FRANCISCO, Calif., April 08, 2024 (GLOBE ...
Standard BioTools Inc.
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
Loading the latest forecasts...